Recently, Pozo et al., based on their experiments involving the pharmacological inhibition of Dyrk1A in tumor‐initiating cells and tumor specimens, suggested that Dyrk1A could represent a promising therapeutic target in EGFR‐dependent glioblastoma.49 Here, DYRK1A is linked to neoplasm.